TGTX Q4 2024 Earnings — TG Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

TGTXTG Therapeutics, Inc.

$5B

Q4 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$108M+146.0% YoY

Gross Profit

$93M85.8% margin

Operating Income

$30M27.7% margin

Net Income

$23M21.6% margin

EPS (Diluted)

$0.15

QoQ Revenue Growth

+29.0%

Cash Flow

Operating Cash Flow

-$26M

Free Cash Flow

-$26M

Stock-Based Comp.

$12M

Balance Sheet

Total Assets

$578M

Total Liabilities

$355M

Stockholders' Equity

$222M

Cash & Equivalents

$180M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$108M	$44M	+146.0%
Gross Profit	$93M	$36M	+157.6%
Operating Income	$30M	-$12M	+339.9%
Net Income	$23M	-$14M	+261.8%

Revenue Segments

Product

$180M99%

Other Revenue

$1M1%

Royalty

$539,0000%

License Revenue

$76,0000%